Erythrocytosis and ADAMTS13 Deficiency: A Complex Intersection of Thrombosis Risk and Hemostatic Imbalance
Abstract Erythrocytosis, characterized by elevated red blood cell mass, and ADAMTS13 deficiency, a central factor in the pathogenesis of Thrombotic Thrombocytopenic Purpura (TTP), may interact in complex ways to influence thrombosis risk. This article explores the biochemical and clinical relationship between erythrocytosis, ADAMTS13 genetic markers, von Willebrand Factor (vWF) abnormalities, and the potential roles of supportive treatments like saline and anticoagulants such as heparin. It also reviews the current understanding of therapeutic strategies for managing patients with these overlapping hematologic abnormalities. Introduction ADAMTS13 (A Disintegrin and Metalloprotease with Thrombospondin type 1 motif, member 13) is a critical enzyme responsible for cleaving ultra-large multimers of von Willebrand Factor (vWF), thus regulating platelet adhesion and aggregation. Deficiency in ADAMTS13 activity, either congenital or acquired, leads to the accumulation of these ult...